Cadila: Racing ahead - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Cadila: Racing ahead

Jul 9, 2002

A 16% rise in turnover reported by Cadila for FY02 is quite encouraging, especially considering the fact that the first half yearly growth was a mere 7%. On an annual basis, operating margins have also shown an improvement. The company has ambitious plans to emerge amongst the top 3 pharmaceutical companies in India by March 2004. Post the acquisition of controlling stake in German Remedies, the company is open to further in-organic growth.

(Rs m)FY01FY02Change
Sales 5,088 5,888 15.7%
Other Income 74 41 -44.1%
Expenditure 4,351 4,997 14.8%
Operating Profit (EBDIT) 737 891 20.9%
Operating Profit Margin (%)14.5%15.1%
Interest (46) 11 -123.8%
Depreciation 149 188 26.1%
Profit before Tax 708 734 3.6%
Tax556212.5%
Profit after Tax/(Loss) 653 672 2.9%
Net profit margin (%)12.8%11.4% 
No. of Shares (eoy) (m)6060 
Diluted Earnings per share*10.911.2 
P/E (at current price) 12.1 

The strong growth rate in the last two quarters has been possible due to launch of new products in the neuroscience division, acquisition of perpetual rights to market five leading brands from Asta and acquisition of 'Aten' brand from Kopran last year. Further, the company has also logged several co-marketing alliances with Kopran, Ranbaxy and E-Merck. However, margins in this business are low compared to other businesses which partially explains the drop in overall margins.Realising its over dependence on few slow growing therapeutic segments, the company has made some rapid moves, including acquisitions, which will strongly position the company in some of the fast growing therapeutic segments. In its bid to further fuel in-organic growth, Cadila acquired the Vadodara-based Banyan Chemicals Ltd (BCL) for Rs 205 m.

The acquisition of BCL is expected to help the company in exploring export markets. BCL already has a US FDA approved unit for the manufacture of bulk drugs with export sales of Rs 250 m to Geneva Pharmaceuticals Technology Corporation of the US, a subsidiary of Novartis. The company plans to rapidly penetrate the export markets in the US through BCL. While the acquisition of BCL would give Cadila direct entry into the US bulk drug market, exports of formulations would take another two years, as the company is in the process of getting US FDA approval for the formulation plant. Cadila has plans to keep BCL as a separate subsidiary, though it may consider merging it with itself later.

It may be recalled that the company acquired a 27.7% stake in German Remedies for a consideration of Rs 1.5 bn last year. It also acquired perpetual rights to market five leading brands from Asta (one of the promoter of German Remedies). Post that the company did an open offer for the shareholders of German Remedies, taking the total stake in the company to 55.4%. The financing of the same would be done through a mix of debt (Rs 2,000 m) and internal accruals. The company has made a secondary open offer for German Remedies shareholders at a price of Rs 300/- per share for acquiring the remaining shareholding (45%) in GRL. In the event of the company's shareholding crossing 90% through the proposed open offer, it plans to seek the delisting of GRL.

Cadila-German Remedies: Merged Picture
Rs mCadila German RemediesMerged Entity*
Net Sales 5,8881,9607,848
Operating Margins (%)15.1%19.1%16.1%
Net Profit672249921
EPS (Rs.)NANA15.4

The in-organic growth strategy of Cadila group has no doubt helped it to create a robust entity. However, what is concerning is the rising interest burden on the company. The debt figure has risen considerably in last one year to fund its acqusitions and research initiatives. The payback period of these acquisitions would have to justify the rise in interest costs. Further, the company has yet to prove its performance in the exports market. The valuations of the company going forward would thus depend on how fast the debt backed acquisitions of the company payoff. At the current market price of Rs 135, the stock trades at 9x its FY02 earnings on a consolidated basis.

Equitymaster requests your view! Post a comment on "Cadila: Racing ahead". Click here!

  

More Views on News

CADILA HEALTHCARE Announces Quarterly Results (1QFY22); Net Profit Up 35.0% (Quarterly Result Update)

Aug 16, 2021 | Updated on Aug 16, 2021

For the quarter ended June 2021, CADILA HEALTHCARE has posted a net profit of Rs 6 bn (up 35.0% YoY). Sales on the other hand came in at Rs 40 bn (up 14.5% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE 2020-21 Annual Report Analysis (Annual Result Update)

Aug 10, 2021 | Updated on Aug 10, 2021

Here's an analysis of the annual report of CADILA HEALTHCARE for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

Cadila Healthcare Reports 73% Rise in Profits (Views On News)

May 28, 2021

A look into the company's quarter four financial performance.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing. (Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.

5 Indian Companies Embracing Blockchain Technology (Views On News)

Nov 23, 2021

Blockchain adoption in India was slow in the past. Now, the technology is being well received.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Dec 3, 2021 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS